Related Experiment Video
Updated: Sep 21, 2025

11:14
Designing Silk-silk Protein Alloy Materials for Biomedical Applications
Published on: August 13, 2014
18.5K
Silk Fibroin-Based Biomaterials for Hemostatic Applications
Md Tipu Sultan1, Heesun Hong1, Ok Joo Lee1
1Nano-Bio Regenerative Medical Institute (NBRM), Hallym University, Chuncheon 24252, Korea.
Biomolecules
|May 28, 2022
Summary
Silk fibroin (SF) shows promise as a hemostatic agent for surgical bleeding control. This review details SF
Area of Science:
- Biomaterials Science
- Surgical Innovation
- Hemostasis Research
Background:
- Effective hemostasis is critical in surgery to prevent mortality from hemorrhage.
- A wide array of topical hemostatic agents exist, with ongoing development in the field.
- Silk fibroin (SF) is a natural protein with established biomedical applications.
Purpose of the Study:
- To review the various morphologic forms of silk fibroin (SF).
- To summarize recent technological advancements in SF-based hemostatic agents.
- To highlight the potential of SF as a surgical hemostat.
Main Methods:
- Literature review of studies on silk fibroin (SF) and hemostatic agents.
- Analysis of morphologic characteristics of SF relevant to hemostasis.
- Synthesis of information on technological developments in SF-based hemostats.
Main Results:
- Silk fibroin (SF) exhibits diverse morphologic forms suitable for hemostatic applications.
- Recent advancements focus on optimizing SF structures and formulations for enhanced efficacy.
- SF has demonstrated potential as a viable hemostatic agent in various research settings.
Conclusions:
- Silk fibroin (SF) represents a promising biomaterial for developing novel hemostatic agents.
- Further research and technological innovation can optimize SF-based hemostats for surgical use.
- SF-based hemostats offer a potential alternative to existing agents for controlling surgical bleeding.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
938
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
938
Introduction to Hemostasis
9.0K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
9.0K
Extrinsic and Intrinsic Pathways of Hemostasis
9.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.3K

